Kornimate/medical-research-clean huggingface dataset:
nasal photodisinfection covid-19 proof of concept study

Conditions: COVID-19; Corona Virus Infection; SARS-CoV 2

Summary: the study proposes to test photodisinfection (pdf) on sars-cov-2 in the nose. the study will use health canada approved steriwave™ nasal decolonization (nd) in he nostril of patients infected with sars-cov-2. participants are swabbed for sars-cov-2 before and after the pdf treatment. for the study, a small group of healthcare workers who have tested positive for sars-cov-2 will be included. they will not undergo the treatment but will need to swab their noses multiple times over the next 5 days. this nil group will provide the effect (if any) of swabbing sars-cov-2 levels in the nose.

the study proposes to test photodisinfetion (pdf) on levels of sars-cov-2 in the nose. the study will use health canada approved steriwave™ nasal decolonization (nd) in patients infected with sars-cov-2 . currrently, pdf is being used at some institutions before surgery to lower the risk of postoperative infection. pdf uses a methylene blue (mb) nasal spray, followed by 5 minutes of red-light exposure through a small light-diffusing applicator. this will need to be placed into each nostril. participants are swabbed for sars-cov-2 before and after treatment. in addition to the patients testing positive for sars-cov-2, there will also be a small group of healthcare workers who have tested positive that will be included. though they are not undergoing treatment, they will swab their own noses multiple times over a period of 5 days. this will allow us to evaluate the effect (if any) of swabbing on sars-cov-2 levels in the nose. the study hypothesis is that mb-mediated pdf will show the ability to kill sars-cov-2 which will consequently confirm its efficacy as a first line defense against the virus.

Eligibility criteria:
inclusion criteria (patient population): * recent sars-cov-2+ diagnosis * present in hospital inclusion criteria (healthcare workers): * recent sars-cov-2+ diagnosis * ability to self-administer nasal swabs exclusion criteria (patient population): * immediate requirement for intubation (i.e. emergency airway) or inability to maintain independent oral airway exclusion criteria (healthcare workers): * none

Keywords: covid-19 sars-cov-2 coronavirus influenza photodisinfection nasal photodisinfection
jail-based impact of crime intervention

Conditions: Substance Abuse; HIV Risk; Criminogenic Thinking; Shame; Guilt; Empathy

Summary: the purpose of this study is to evaluate whether the impact of crime (ioc) group intervention with jail inmates reduces post-release recidivism, substance abuse, and hiv risk behavior.

this project imports social-personality theory and research on moral emotions and cognitions to the applied problems of crime, substance abuse, and hiv risk behavior. the primary aim of this study, a phase 2 randomized clinical trial (rct) of the restorative justice-inspired impact of crime (ioc) group intervention, is to examine the efficacy of treatment and to determine if changes in moral emotions and cognitions serve as mechanisms of action, explaining the impact of treatment involvement on reductions in post-release recidivism, substance abuse, and hiv risk behavior.

Eligibility criteria:
inclusion criteria: * must be 18 years or older * must be male * must be currently incarcerated jail inmate * must be sentenced * sentence must be short enough to serve out sentence at adc * release date must follow projected final session of treatment * must speak, read, and write in english with sufficient proficiency to use workbook and participate in group sessions * must be assigned to the jail's "general population" exclusion criteria: * actively psychotic * assigned "keep separate" from other group members

Keywords: criminal behavior substance abuse hiv risk behavior criminogenic thinking shame guilt empathy jail inmates restorative justice crime
impact of neutrophil extracellular traps on tissue plasminogen activator induced thrombolysis in acute ischemic stroke patients

Conditions: Acute Stroke

Summary: acute ischemic stroke (ais) remains a leading cause of adult disability, cognitive impairment and mortality worldwide despite the development of revascularization therapies (intravenous tissue plasminogen activator (t-pa) and endovascular therapy). thrombosis resistance after iv t-pa therapy is frequent especially in case of ais with proximal occlusion. in recent years, neutrophil extracellular traps (nets) have been identified as major triggers and structural factors of various forms of thrombosis. nets are extracellular webs primarily composed of dna from neutrophils. a recent study shows that the nets burden in coronary thrombi is positively correlated with the infarct size and negatively correlated with electrocardiogram (st-segment) resolution. this later study revealed that in vitro addition of dnase i accelerated the t-pa-induced thrombolysis of coronary thrombi. nets could, in consequence, be promising targets for improved thrombolysis in ais. the aim of this study is to assess the impact of nets composition of thrombi retrieved during endovascular therapy in ais patients on iv t-pa induced thrombolysis, clinical outcome and ais etiologies.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * ais secondary to a large vessel occlusion * admitted for endovascular therapy. exclusion criteria: * pregnant or breast feeding patient patient under legal protection * patient opposition to participate in this study
tab block and patient controlled analgesia in cs

Conditions: Analgesia

Summary: cesarean section rate become increasing nowadays

indication of cesarean section are different from case to case and the use of pain controlling agents is very important to relieve post operative pain

Eligibility criteria:
inclusion criteria: * women coming for an elective cs exclusion criteria: * women who has a n emergency cs or complicated normal deivery needs urgent cs
efficacy and safety of fluvastatin in children with heterozygous familial hypercholesterolemia

Conditions: Heterozygous Familial Hypercholesterolemia; Mixed Dyslipidemia

Summary: the purpose of the study is to assess the safety and efficacy of fluvastatin in children diagnosed with heterozygous familial hypercholesterolemia


Eligibility criteria:
inclusion criteria: * 10-16 years old heterozygous familial hypercholesterolemia exclusion criteria: * homozygous familial hypercholesterolemia pregnant or lactating females major surgery during the six month prior study other protocol defined inclusion and exclusion criteria may apply

Keywords: heterozygous familial hypercholesterolemia mixed dyslipidemia
consequences of post stroke polysomnographic abnormalities on functionnal recovery and survival after an ischemic stroke

Conditions: Ischemic Stroke; Cerebral Infarct; Sleep Apnea; Periodic Limb Movement Disorder

Summary: ischemic stroke is a major public health issue, likely to cause functional disability. it is well known that sleep has an impact on brain plasticity, and after an ischemic stroke, studies have shown subjective sleep quality alterations and sleep architecture abnormalities. furthermore, there is no clear guideline showing the usefulness of a systematic sleep investigation following an ischemic stroke. the aim of the study is to identify retrospectively correlation between polysomnographic abnormalities (sleep apnea, periodic limb movements, disturbed sleep architecture...) and functional recovery after an ischemic stroke. the study also assesses the impact of sleep abnormalities on survival, and the risk of new cardiovascular event.

this study is a retrospective observational study, from a cohort of patients who had a sleep recording (polysomnography or ventilatory polygraphy performed in montpellier university hospital) following an ischemic stroke.

Eligibility criteria:
inclusion criteria: * men and women, more than 18 years old * medical history of ischemic stroke * who had a sleep recording following the stroke exclusion criteria: * others types of strokes (bleeding, transient ischemic attack, cerebal veinous thrombosis) * patients less than 18 years old

Keywords: functional recovery ischemic stroke / cerebral infarct sleep polysomnography
endovascular treatment of wide neck intracranial aneurysms with the leo + stent : the leo + ii cohort study

Conditions: Intracranial Aneurysm

Summary: this is a prospective, multicenter, single-arm observational study to evaluate the efficacy and the morbi-mortality of leo + in patients with wide neck intracranial aneurysms (fusiform, saccular or dissecting), ruptured or not ruptured.


Eligibility criteria:
inclusion criteria: * all patients with ruptured or not ruptured intracranial aneurysms demonstrated by cerebral arteriography treated with leo + stent * patients (or their parents for minors) must be informed and give written consent exclusion criteria: * patients (or parents) who refused to give consent.
safety and explore the efficacy of multiple doses of furestem-ad inj. for moderate to severe chronic atopic dermatitis

Conditions: Atopic Dermatitis

Summary: a phase i/iia clinical trial to evaluate the safety and explore the efficacy of multiple doses of furestem-ad inj. for moderate to severe chronic atopic dermatitis

phase 1: multicenter, repeated administration, disclosure, dose escalation, evaluate safety and tolerability and explore efficacy phase 2a: multicenter, repeated administration, random assignment, double blinding, parallel, efficacy and safety are evaluated for repeated administration compared to placebo and single administration.

Eligibility criteria:
inclusion criteria: 1. of either gender, aged \>=19 2. atopic dermatitis subjects who are coincident with hanifin and rajka diagnosis criteria 3. chronic atopic dermatitis that has been present for at least 3 years 4. easi\>=16 at screening and baseline visit 5. iga\>=3, scorad index\>=25, bsa \>=10% of ad involvement at screegning and baseline visit 6. subjects with documented record of inadequate response to the stable use of topical atopic dermatitis treatment within 24 weeks before participating in the study, or whom are inadvisable due to safety risks 7. subjects who understand and voluntarily sign an informed consent form exclusion criteria: 1. subjects with medical history or surgery/procedure history 2. subjects with diseases at the time of participation in this study (systemic infection, other serious skin disorders, pigmentation or extensive scarring in atopic dermatitis symptom region) 3. renal dysfunction with creatinine \>2.0 mg/dl at screening 4. hepatic dysfunction with alt or ast levels 2.5 times higher than the normal range at screening 5. alc\<800/mm3 at screening 6. subjects with live vaccine administration within 12 weeks before baseline 7. receipt of leukotriene receptor antagonists, systemic steroids, systemic or topical antihistamines, phototherapy, or systemic immunosuppressants/modulators including janus kinase (jak) inhibitors, and/or any other systemic therapy within 4 weeks before baseline 8. receipt of topical steroids(class1\~6), topical tacrolimus or pimecrolimus within 2 weeks before baseline 9. subjects who need prohibited medication during clinical period 10. pregnant, breast-feeding women or women who plan to become pregnant during this study 11. subjects who currently participate in other clinical trial or participated in other clinical trial within 4 weeks 12. subjects with experience of administering furestem-ad inj. 13. any other condition which the investigator judges would make patient unsuitable for study participation

Keywords: hucb-msc atopic dermatitis
nis register study comparing seroquel and seroquel prolong

Conditions: Comparing Hospitalisation Time With Seroquel and Seroquel Prolong

Summary: the general aim of this non interventional study is to clarify what are the current clinical treatment practices of quetiapine immediate release and quetiapine extended release. the primary objectives of the study are:1.to collect information on the used quetiapine immediate release or quetiapine extended release medication 2.to collect information on duration and number of hospitalisation days 3.change of gaf points


Eligibility criteria:
inclusion criteria: * medication: seroquel or seroquel prolong * diagnosis: f20-f29 or f30-f31 (icd-10) * in-patient exclusion criteria: * none

Keywords: schizophrenia bipolar disorder manic disorder register study quetiapine quetiapine prolong seroquel seroquel prolong seroquel xr in-patient
compare the effect on cognitive functioning of two formulations of seroquel, seroquel xr and ir in patients with stable schizophrenia

Conditions: Schizophrenia

Summary: this will be a phase iv 20 -32 day prospective, double blind, double-dummy, randomised crossover study that will evaluate the effect of quetiapine xr and quetiapine ir on cognitive performance in patients with schizophrenia stabilized on a single antipsychotic medication.


Eligibility criteria:
inclusion criteria: * provision of written informed consent prior to any study specific procedures * documented clinical diagnosis of schizophrenia, paranoid type, for at least 2 years before randomisation meeting the diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv, american psychiatric association 2000) criteria of schizophrenia (dsm-iv codes 295.3) confirmed by mini version 5.0 * outpatient status at enrolment * dose of quetiapine ir or quetiapine xr unchanged during the last 56 days before randomisation exclusion criteria: * diagnosis of any dsm-iv axis i disorder other than those included in inclusion criteria above within 6 months before randomisation (e.g., alcohol dependence or psychoactive substance dependence not in full remission, concurrent organic mental disorder, or mental retardation \[axis ii diagnosis\]) of a degree that may interfere with the patient's ability to co-operate. * previous stable use of high dosage of benzodiazepines during one year or more * significant neurological medical history (complicated head trauma as judged by the investigator, epilepsy, meningo-encephalitis) * use of the following medication: * other antipsychotic drug than quetiapine within 28 days prior to randomisation * a depot antipsychotic injection within two dosing intervals (for the depot) before randomisation (visit 2) * other psychoactive drugs within 14 days prior to randomisation (hypnotic or anxiolytic drugs, other than those allowed) * use of concomitant therapy likely to affect cognition, medication prohibited 28 days prior to randomisation: benzodiazepines, amphetamines, reboxitin, atomoxinetine, buspiron, donepezil, duloxetine, galantamine, ginko biloba, memantine, methylphenidate, modafinil, rivastigmine, tacrine, smoking cessation therapy varencicline and any dosage form of nicotine replacement therapy. medication prohibited 14 days prior to randomisation: irreversible monoamine oxidase inhibitors (maoi), tricyclic antidepressants (tca), biperiden, antoicholinergic agents (even if the indications are extra pyramidal symptoms or urinary symptoms)

Keywords: stable schizophrenia cognitive functioning
pregnancy remote monitoring of women at risk for gestational diabetes

Conditions: Pregnancy Diabetic

Summary: background: remote monitoring (rm) is a new screenings- and or diagnostic tool in healthcare. in 2015, the premom study (pregnancy remote monitoring), in which patients with gestational hypertensive diseases did received a rm prenatal follow up, has started. the first results showed an added value of rm in the prenatal follow-up. due to these results, a rm program for pregnant women with gestational diabetes mellitus (gdm) will be developed and evaluated. protocol: women (at risk of) gdm will be included in this study. they receive a ihealth align (a glucose monitor) and associated glycemiestrips. the app of ihealth will be downloaded on the pregnant women's smartphone to collect the data and to send them to the researcher in the hospital. the women is asked to perform four glycemie controls/day (sober and two hours after every mail) with the received glucose monitor. the monitor is connected via wi-fi and bluetooth with the computer of the researches who controls and evaluated these data. additionally, the pregnant women has to check daily her body weight with a weight scale of her own. they have to upload these data manually in the app on her smartphone. when the pregnant women has an prenatal consultation, an overview with the data will be send to the responsible gynecologist. the gynecologist will also be alarmed when the pregnant women has three abnormal values at the same moment of the day (ex. every morning after breakfast). when necessary, advice among life-style can be given or a referral to an endocrinologist can be made. the researches will not perform interventions by herself, only the responsible doctor can do this. by analyzing the patients parameters when she's at home, a better vision can be achieved of the health of the mother and the child. this study will be conducted as a first research to get a better insight in the added value of rm in pregnancies complicated with gdm.


Eligibility criteria:
inclusion criteria: * women with confirmed gdm or at risk for this disease. pregnancies \> 10 weeks of gestation, primipara and multipara. exclusion criteria: * pregnancies \< 10 weeks of gestation, congenital malformations of the fetus
methylene blue treatment of chronic hepatitis b virus infection

Conditions: Chronic HBV Infection

Summary: hbv infection is a global public health problem. it is estimated that there are more than 250 million hbv carriers worldwide, of whom approximately 600,000 die each year from hbv-related liver disease. diagnosis and treatment depend on the stage of infection, the degree of liver inflammation, and the progression of fibrosis. patients with hbeag-positive or -negative hepatitis are usually treated with nucleos(-t)ide analogues. this treatment inhibits hbv reverse transcriptase and reduces viral replication, but does not affect hbsag production. treatment must be continued for life in most cases and is associated with high cumulative costs and the risk of development of resistance. recently, it has been shown that patients who show a decrease in their hbsag levels are more likely to become hbsag negative, seroconvert and be able to stop antiviral treatment, which is the ultimate goal of treatment, but unfortunately rarely achieved. methylene blue (mb) has been shown to have an effect on hbsag levels in vitro, making it a promising test for a new treatment for hbv. this is an explorative pilot study, open label, dose-escalation, single center clinical trial on the efficacy of mb against hbv infection. primary objective is to assess the efficacy of incremental doses of mb against hepatitis b virus in patients with chronic hepatitis b assessed by the reduction of both the hbsag and hbv dna levels after 6 months of treatment and 6 months of follow-up. participant will be treated for 6 months with mb 100 mg capsules, and then followed up for a further 6 months. the initial dose of mb might be increased if the patient is a non-responder.


Eligibility criteria:
inclusion criteria: * signed informed consent * age ≥ 18 and \< 80 years * microbiologically confirmed chronic hepatitis b virus infection (according to the old terminology "inactive hbv carrier") * hbsag levels within 20-15'000 iu/ml measured at the at least twice at 6-18 months apart * hbv dna pcr levels within 1'000-20'000 iu/ml measured at least twice at 6-18 months apart * negative pregnancy test in women of child-bearing age exclusion criteria: * documented refusal to participate in the study * known g-6-phophatase deficiency * treatment with a serotoninergic drug * ongoing treatment with a nucleos(-t)ide treatment * clinically relevant concomitant liver disease * gpt \> 2xuln * fibroscan of \> 8.0 kpa obtained ≤ 12 months before visit 0/screening * hbeag positivity * anti hdv antibody positivity * breastfeeding women

Keywords: hbv chronic hbv methylene blue mb
postoperative electrical muscle stimulation (poems)

Conditions: Muscle Atrophy; Postoperative Complications

Summary: patients lose a significant amount of muscle following major abdominal surgery. this is partly due to a catabolic response to the surgical insult and inflammation, but is also probably due to a lack of muscle use secondary to immobility. this study will aim to assess whether some or even all of postoperative muscle loss in the upper leg muscle group is preventable through electrical muscle stimulation to mimic physical activity.

following major gastrointestinal surgery patients may loose around 6 % of their skeletal muscle mass in the first 5 days. whilst some of this loss is as a result of inflammation and starvation, some is due to muscle disuse. studies have shown that patients spend 96% of their time being sedentary in the first 5 days following major abdominal surgery and by day 5 are still taking a median of less than 500 steps per day. studies of healthy volunteers who undergo similar muscle disuse loose approximately 3.5% of skeletal muscle mass over the same time period, indicating that around half of postoperative muscle loss may be due to immobility. through the use of electrical muscle stimulation, this study will aim to mimic high levels of exercise in the quadriceps of patients who have undergo major gastrointestinal surgery to see whether this reduces or prevents muscle loss. patients muscles will be measured using ultrasound and dxa and neuromuscular function will be measured using electromyography.

Eligibility criteria:
inclusion criteria: * adult patients undergoing major segmental colonic resections or gastric/oesophageal resection * sufficient mobility and fitness to complete normal enhanced recovery protocols following surgery * ability to give informed consent exclusion criteria: * pre-existing neuromuscular disease (including parkinson's disease) * pacemaker, implantable cardiac defibrillator or other implanted nerve stimulator device * metalwork in both upper legs * dementia * inability to give informed consent * disability preventing normal mobilisation after surgery * symptomatic peripheral vascular disease * chronic kidney failure of chronic heart failure * intubation for \> 24 hours post operation * return to theatre for surgical complication within first 5 days post operation

Keywords: muscle atrophy postoperative disuse electrical muscle stimulation